Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Fish and Richardson
Queensland Health
Moodys
Medtronic
Julphar
Mallinckrodt
UBS
Cipla

Generated: September 20, 2018

DrugPatentWatch Database Preview

Cubist Pharms Llc Company Profile

« Back to Dashboard

What is the competitive landscape for CUBIST PHARMS LLC, and what generic alternatives to CUBIST PHARMS LLC drugs are available?

CUBIST PHARMS LLC has five approved drugs.

There are seventeen US patents protecting CUBIST PHARMS LLC drugs.

Summary for Cubist Pharms Llc
US Patents:17
Tradenames:5
Ingredients:4
NDAs:5

Drugs and US Patents for Cubist Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes 9,872,906 ➤ Try a Free Trial Y ➤ Try a Free Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes 7,129,232 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cubist Pharms Llc SIVEXTRO tedizolid phosphate POWDER;INTRAVENOUS 205436-001 Jun 20, 2014 RX Yes Yes 8,426,389 ➤ Try a Free Trial Y Y ➤ Try a Free Trial
Cubist Pharms Llc SIVEXTRO tedizolid phosphate POWDER;INTRAVENOUS 205436-001 Jun 20, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial
Cubist Pharms Llc ZERBAXA ceftolozane sulfate; tazobactam sodium POWDER;INTRAVENOUS 206829-001 Dec 19, 2014 RX Yes Yes 8,968,753 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for Cubist Pharms Llc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 5,912,226 ➤ Try a Free Trial
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003 RE39071 ➤ Try a Free Trial
Cubist Pharms Llc CUBICIN daptomycin POWDER;INTRAVENOUS 021572-002 Sep 12, 2003 RE39071 ➤ Try a Free Trial
Cubist Pharms Llc CUBICIN daptomycin POWDER;IV (INFUSION) 021572-001 Sep 12, 2003 5,912,226 ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for CUBIST PHARMS LLC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Tablets 200 mg ➤ Subscribe 2015-05-27
➤ Subscribe For Injection 500 mg/vial ➤ Subscribe 2008-11-19

Non-Orange Book US Patents for Cubist Pharms Llc

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,507,564 Tiacumicin production ➤ Try a Free Trial
9,163,043 Oxazolidinone derivatives ➤ Try a Free Trial
8,883,986 Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof ➤ Try a Free Trial
8,728,796 Tiacumicin production ➤ Try a Free Trial
9,624,250 Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for Cubist Pharms Llc Drugs

Country Document Number Estimated Expiration
Eurasian Patent Organization 029090 ➤ Try a Free Trial
Canada 2781666 ➤ Try a Free Trial
World Intellectual Property Organization (WIPO) 2007048059 ➤ Try a Free Trial
European Patent Office 2070530 ➤ Try a Free Trial
Japan 2012516894 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for Cubist Pharms Llc Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
943 Luxembourg ➤ Try a Free Trial PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
684 Luxembourg ➤ Try a Free Trial PRODUCT NAME: FIDAXOMICINE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20111207
2015032 Lithuania ➤ Try a Free Trial PRODUCT NAME: TEDIZOLIDO FOSFATAS; REGISTRATION NO/DATE: EU/1/15/991 20150323
2015032,C1699784 Lithuania ➤ Try a Free Trial PRODUCT NAME: TEDIZOLIDAS, PASIRINKTINAI ESTERIO PAVIDALU, YPAC FOSFATO ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/15/991 20150323
2015 00048 Denmark ➤ Try a Free Trial PRODUCT NAME: TEDIZOLID, OPTIONALLY IN THE FORM OF AN ESTER, IN PARTICULAR A PHOSPHATE, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING TEDIZOLID PHOSPHATE; REG. NO/DATE: EU/1/15/991 20150325
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Healthtrust
Moodys
Accenture
Argus Health
Chinese Patent Office
Cantor Fitzgerald
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.